Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143806 · ClinicalTrials.gov registry record · Phase 2
Transitioning From Cyclosporine to Alefacept in Psoriasis
A Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00143806 is a Phase 2 study that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 13 participants.
The verdict
NCT00143806, a Phase 2 study, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.
Interventions
- DRUG Transitioning patients from cyclosporine to alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143806
The ClinicalTrials.gov registry entry for NCT00143806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transitioning patients from cyclosporine to alefacept is the first listed.
NCT00143806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143806 about?
NCT00143806 is a clinical study titled "Transitioning From Cyclosporine to Alefacept in Psoriasis". The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.
What is the current status of trial NCT00143806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2003-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00143806?
The interventions under investigation include: Transitioning patients from cyclosporine to alefacept (DRUG).
Who is sponsoring clinical trial NCT00143806?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.